Global Drugs for Vulvovaginal Candidiasis Market Growth 2022-2028
As the global economy mends, the 2021 growth of Drugs for Vulvovaginal Candidiasis will have significant change from previous year. According to our latest study, the global Drugs for Vulvovaginal Candidiasis market size is USD million in 2022 from USD 798.8 million in 2021, with a change of % between 2021 and 2022. The global Drugs for Vulvovaginal Candidiasis market size will reach USD 890 million in 2028, growing at a CAGR of 1.6% over the analysis period.
The United States Drugs for Vulvovaginal Candidiasis market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Drugs for Vulvovaginal Candidiasis market, reaching US$ million by the year 2028. As for the Europe Drugs for Vulvovaginal Candidiasis landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Drugs for Vulvovaginal Candidiasis players cover Bayer, Perrigo, J & J, and Pfizer, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Vulvovaginal Candidiasis market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Cream
Pessary
Other
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Hospital & Clinic
Pharmacy
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Drugs for Vulvovaginal Candidiasis Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Drugs for Vulvovaginal Candidiasis by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Drugs for Vulvovaginal Candidiasis by Country/Region, 2017, 2022 & 2028
2.2 Drugs for Vulvovaginal Candidiasis Segment by Type
2.2.1 Cream
2.2.2 Pessary
2.2.3 Other
2.3 Drugs for Vulvovaginal Candidiasis Sales by Type
2.3.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2017-2022)
2.3.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Type (2017-2022)
2.3.3 Global Drugs for Vulvovaginal Candidiasis Sale Price by Type (2017-2022)
2.4 Drugs for Vulvovaginal Candidiasis Segment by Application
2.4.1 Hospital & Clinic
2.4.2 Pharmacy
2.5 Drugs for Vulvovaginal Candidiasis Sales by Application
2.5.1 Global Drugs for Vulvovaginal Candidiasis Sale Market Share by Application (2017-2022)
2.5.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Application (2017-2022)
2.5.3 Global Drugs for Vulvovaginal Candidiasis Sale Price by Application (2017-2022)
3 Global Drugs for Vulvovaginal Candidiasis by Company
3.1 Global Drugs for Vulvovaginal Candidiasis Breakdown Data by Company
3.1.1 Global Drugs for Vulvovaginal Candidiasis Annual Sales by Company (2020-2022)
3.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2020-2022)
3.2 Global Drugs for Vulvovaginal Candidiasis Annual Revenue by Company (2020-2022)
3.2.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Company (2020-2022)
3.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Company (2020-2022)
3.3 Global Drugs for Vulvovaginal Candidiasis Sale Price by Company
3.4 Key Manufacturers Drugs for Vulvovaginal Candidiasis Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Drugs for Vulvovaginal Candidiasis Product Location Distribution
3.4.2 Players Drugs for Vulvovaginal Candidiasis Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Drugs for Vulvovaginal Candidiasis by Geographic Region
4.1 World Historic Drugs for Vulvovaginal Candidiasis Market Size by Geographic Region (2017-2022)
4.1.1 Global Drugs for Vulvovaginal Candidiasis Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Drugs for Vulvovaginal Candidiasis Annual Revenue by Geographic Region
4.2 World Historic Drugs for Vulvovaginal Candidiasis Market Size by Country/Region (2017-2022)
4.2.1 Global Drugs for Vulvovaginal Candidiasis Annual Sales by Country/Region (2017-2022)
4.2.2 Global Drugs for Vulvovaginal Candidiasis Annual Revenue by Country/Region
4.3 Americas Drugs for Vulvovaginal Candidiasis Sales Growth
4.4 APAC Drugs for Vulvovaginal Candidiasis Sales Growth
4.5 Europe Drugs for Vulvovaginal Candidiasis Sales Growth
4.6 Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Growth
5 Americas
5.1 Americas Drugs for Vulvovaginal Candidiasis Sales by Country
5.1.1 Americas Drugs for Vulvovaginal Candidiasis Sales by Country (2017-2022)
5.1.2 Americas Drugs for Vulvovaginal Candidiasis Revenue by Country (2017-2022)
5.2 Americas Drugs for Vulvovaginal Candidiasis Sales by Type
5.3 Americas Drugs for Vulvovaginal Candidiasis Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Drugs for Vulvovaginal Candidiasis Sales by Region
6.1.1 APAC Drugs for Vulvovaginal Candidiasis Sales by Region (2017-2022)
6.1.2 APAC Drugs for Vulvovaginal Candidiasis Revenue by Region (2017-2022)
6.2 APAC Drugs for Vulvovaginal Candidiasis Sales by Type
6.3 APAC Drugs for Vulvovaginal Candidiasis Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Drugs for Vulvovaginal Candidiasis by Country
7.1.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2017-2022)
7.1.2 Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2017-2022)
7.2 Europe Drugs for Vulvovaginal Candidiasis Sales by Type
7.3 Europe Drugs for Vulvovaginal Candidiasis Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis by Country
8.1.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2017-2022)
8.1.2 Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2017-2022)
8.2 Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales by Type
8.3 Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Drugs for Vulvovaginal Candidiasis
10.3 Manufacturing Process Analysis of Drugs for Vulvovaginal Candidiasis
10.4 Industry Chain Structure of Drugs for Vulvovaginal Candidiasis
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Drugs for Vulvovaginal Candidiasis Distributors
11.3 Drugs for Vulvovaginal Candidiasis Customer
12 World Forecast Review for Drugs for Vulvovaginal Candidiasis by Geographic Region
12.1 Global Drugs for Vulvovaginal Candidiasis Market Size Forecast by Region
12.1.1 Global Drugs for Vulvovaginal Candidiasis Forecast by Region (2023-2028)
12.1.2 Global Drugs for Vulvovaginal Candidiasis Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Drugs for Vulvovaginal Candidiasis Forecast by Type
12.7 Global Drugs for Vulvovaginal Candidiasis Forecast by Application
13 Key Players Analysis
13.1 Bayer
13.1.1 Bayer Company Information
13.1.2 Bayer Drugs for Vulvovaginal Candidiasis Product Offered
13.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Bayer Main Business Overview
13.1.5 Bayer Latest Developments
13.2 Perrigo
13.2.1 Perrigo Company Information
13.2.2 Perrigo Drugs for Vulvovaginal Candidiasis Product Offered
13.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Perrigo Main Business Overview
13.2.5 Perrigo Latest Developments
13.3 J & J
13.3.1 J & J Company Information
13.3.2 J & J Drugs for Vulvovaginal Candidiasis Product Offered
13.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 J & J Main Business Overview
13.3.5 J & J Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Drugs for Vulvovaginal Candidiasis Product Offered
13.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Bristol-Myers Squibb
13.5.1 Bristol-Myers Squibb Company Information
13.5.2 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Offered
13.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Bristol-Myers Squibb Main Business Overview
13.5.5 Bristol-Myers Squibb Latest Developments
13.6 Effik
13.6.1 Effik Company Information
13.6.2 Effik Drugs for Vulvovaginal Candidiasis Product Offered
13.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Effik Main Business Overview
13.6.5 Effik Latest Developments
13.7 Teva
13.7.1 Teva Company Information
13.7.2 Teva Drugs for Vulvovaginal Candidiasis Product Offered
13.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Teva Main Business Overview
13.7.5 Teva Latest Developments
13.8 Sanofi
13.8.1 Sanofi Company Information
13.8.2 Sanofi Drugs for Vulvovaginal Candidiasis Product Offered
13.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Sanofi Main Business Overview
13.8.5 Sanofi Latest Developments
13.9 Cisen Pharmaceutical
13.9.1 Cisen Pharmaceutical Company Information
13.9.2 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Offered
13.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Cisen Pharmaceutical Main Business Overview
13.9.5 Cisen Pharmaceutical Latest Developments
13.10 Kingyork Group
13.10.1 Kingyork Group Company Information
13.10.2 Kingyork Group Drugs for Vulvovaginal Candidiasis Product Offered
13.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Kingyork Group Main Business Overview
13.10.5 Kingyork Group Latest Developments
14 Research Findings and Conclusion
List of Tables
Table 1. Drugs for Vulvovaginal Candidiasis Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Drugs for Vulvovaginal Candidiasis Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Cream
Table 4. Major Players of Pessary
Table 5. Major Players of Other
Table 6. Global Drugs for Vulvovaginal Candidiasis Sales by Type (2017-2022) & (K Units)
Table 7. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2017-2022)
Table 8. Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2017-2022) & ($ million)
Table 9. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2017-2022)
Table 10. Global Drugs for Vulvovaginal Candidiasis Sale Price by Type (2017-2022) & (USD/Unit)
Table 11. Global Drugs for Vulvovaginal Candidiasis Sales by Application (2017-2022) & (K Units)
Table 12. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2017-2022)
Table 13. Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2017-2022)
Table 14. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2017-2022)
Table 15. Global Drugs for Vulvovaginal Candidiasis Sale Price by Application (2017-2022) & (USD/Unit)
Table 16. Global Drugs for Vulvovaginal Candidiasis Sales by Company (2020-2022) & (K Units)
Table 17. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Company (2020-2022)
Table 18. Global Drugs for Vulvovaginal Candidiasis Revenue by Company (2020-2022) ($ Millions)
Table 19. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Company (2020-2022)
Table 20. Global Drugs for Vulvovaginal Candidiasis Sale Price by Company (2020-2022) & (USD/Unit)
Table 21. Key Manufacturers Drugs for Vulvovaginal Candidiasis Producing Area Distribution and Sales Area
Table 22. Players Drugs for Vulvovaginal Candidiasis Products Offered
Table 23. Drugs for Vulvovaginal Candidiasis Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Drugs for Vulvovaginal Candidiasis Sales by Geographic Region (2017-2022) & (K Units)
Table 27. Global Drugs for Vulvovaginal Candidiasis Sales Market Share Geographic Region (2017-2022)
Table 28. Global Drugs for Vulvovaginal Candidiasis Revenue by Geographic Region (2017-2022) & ($ millions)
Table 29. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Geographic Region (2017-2022)
Table 30. Global Drugs for Vulvovaginal Candidiasis Sales by Country/Region (2017-2022) & (K Units)
Table 31. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Country/Region (2017-2022)
Table 32. Global Drugs for Vulvovaginal Candidiasis Revenue by Country/Region (2017-2022) & ($ millions)
Table 33. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country/Region (2017-2022)
Table 34. Americas Drugs for Vulvovaginal Candidiasis Sales by Country (2017-2022) & (K Units)
Table 35. Americas Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2017-2022)
Table 36. Americas Drugs for Vulvovaginal Candidiasis Revenue by Country (2017-2022) & ($ Millions)
Table 37. Americas Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2017-2022)
Table 38. Americas Drugs for Vulvovaginal Candidiasis Sales by Type (2017-2022) & (K Units)
Table 39. Americas Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2017-2022)
Table 40. Americas Drugs for Vulvovaginal Candidiasis Sales by Application (2017-2022) & (K Units)
Table 41. Americas Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2017-2022)
Table 42. APAC Drugs for Vulvovaginal Candidiasis Sales by Region (2017-2022) & (K Units)
Table 43. APAC Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2017-2022)
Table 44. APAC Drugs for Vulvovaginal Candidiasis Revenue by Region (2017-2022) & ($ Millions)
Table 45. APAC Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2017-2022)
Table 46. APAC Drugs for Vulvovaginal Candidiasis Sales by Type (2017-2022) & (K Units)
Table 47. APAC Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2017-2022)
Table 48. APAC Drugs for Vulvovaginal Candidiasis Sales by Application (2017-2022) & (K Units)
Table 49. APAC Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2017-2022)
Table 50. Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2017-2022) & (K Units)
Table 51. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2017-2022)
Table 52. Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2017-2022) & ($ Millions)
Table 53. Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2017-2022)
Table 54. Europe Drugs for Vulvovaginal Candidiasis Sales by Type (2017-2022) & (K Units)
Table 55. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2017-2022)
Table 56. Europe Drugs for Vulvovaginal Candidiasis Sales by Application (2017-2022) & (K Units)
Table 57. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2017-2022)
Table 58. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2017-2022) & (K Units)
Table 59. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2017-2022)
Table 60. Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2017-2022) & ($ Millions)
Table 61. Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2017-2022)
Table 62. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales by Type (2017-2022) & (K Units)
Table 63. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2017-2022)
Table 64. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales by Application (2017-2022) & (K Units)
Table 65. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2017-2022)
Table 66. Key Market Drivers & Growth Opportunities of Drugs for Vulvovaginal Candidiasis
Table 67. Key Market Challenges & Risks of Drugs for Vulvovaginal Candidiasis
Table 68. Key Industry Trends of Drugs for Vulvovaginal Candidiasis
Table 69. Drugs for Vulvovaginal Candidiasis Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Drugs for Vulvovaginal Candidiasis Distributors List
Table 72. Drugs for Vulvovaginal Candidiasis Customer List
Table 73. Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Region (2023-2028) & (K Units)
Table 74. Global Drugs for Vulvovaginal Candidiasis Sales Market Forecast by Region
Table 75. Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Region (2023-2028) & ($ millions)
Table 76. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share Forecast by Region (2023-2028)
Table 77. Americas Drugs for Vulvovaginal Candidiasis Sales Forecast by Country (2023-2028) & (K Units)
Table 78. Americas Drugs for Vulvovaginal Candidiasis Revenue Forecast by Country (2023-2028) & ($ millions)
Table 79. APAC Drugs for Vulvovaginal Candidiasis Sales Forecast by Region (2023-2028) & (K Units)
Table 80. APAC Drugs for Vulvovaginal Candidiasis Revenue Forecast by Region (2023-2028) & ($ millions)
Table 81. Europe Drugs for Vulvovaginal Candidiasis Sales Forecast by Country (2023-2028) & (K Units)
Table 82. Europe Drugs for Vulvovaginal Candidiasis Revenue Forecast by Country (2023-2028) & ($ millions)
Table 83. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Forecast by Country (2023-2028) & (K Units)
Table 84. Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2023-2028) & (K Units)
Table 86. Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Type (2023-2028)
Table 87. Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 88. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share Forecast by Type (2023-2028)
Table 89. Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2023-2028) & (K Units)
Table 90. Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Application (2023-2028)
Table 91. Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 92. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share Forecast by Application (2023-2028)
Table 93. Bayer Basic Information, Drugs for Vulvovaginal Candidiasis Manufacturing Base, Sales Area and Its Competitors
Table 94. Bayer Drugs for Vulvovaginal Candidiasis Product Offered
Table 95. Bayer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 96. Bayer Main Business
Table 97. Bayer Latest Developments
Table 98. Perrigo Basic Information, Drugs for Vulvovaginal Candidiasis Manufacturing Base, Sales Area and Its Competitors
Table 99. Perrigo Drugs for Vulvovaginal Candidiasis Product Offered
Table 100. Perrigo Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 101. Perrigo Main Business
Table 102. Perrigo Latest Developments
Table 103. J & J Basic Information, Drugs for Vulvovaginal Candidiasis Manufacturing Base, Sales Area and Its Competitors
Table 104. J & J Drugs for Vulvovaginal Candidiasis Product Offered
Table 105. J & J Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 106. J & J Main Business
Table 107. J & J Latest Developments
Table 108. Pfizer Basic Information, Drugs for Vulvovaginal Candidiasis Manufacturing Base, Sales Area and Its Competitors
Table 109. Pfizer Drugs for Vulvovaginal Candidiasis Product Offered
Table 110. Pfizer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 111. Pfizer Main Business
Table 112. Pfizer Latest Developments
Table 113. Bristol-Myers Squibb Basic Information, Drugs for Vulvovaginal Candidiasis Manufacturing Base, Sales Area and Its Competitors
Table 114. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Offered
Table 115. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 116. Bristol-Myers Squibb Main Business
Table 117. Bristol-Myers Squibb Latest Developments
Table 118. Effik Basic Information, Drugs for Vulvovaginal Candidiasis Manufacturing Base, Sales Area and Its Competitors
Table 119. Effik Drugs for Vulvovaginal Candidiasis Product Offered
Table 120. Effik Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 121. Effik Main Business
Table 122. Effik Latest Developments
Table 123. Teva Basic Information, Drugs for Vulvovaginal Candidiasis Manufacturing Base, Sales Area and Its Competitors
Table 124. Teva Drugs for Vulvovaginal Candidiasis Product Offered
Table 125. Teva Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 126. Teva Main Business
Table 127. Teva Latest Developments
Table 128. Sanofi Basic Information, Drugs for Vulvovaginal Candidiasis Manufacturing Base, Sales Area and Its Competitors
Table 129. Sanofi Drugs for Vulvovaginal Candidiasis Product Offered
Table 130. Sanofi Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 131. Sanofi Main Business
Table 132. Sanofi Latest Developments
Table 133. Cisen Pharmaceutical Basic Information, Drugs for Vulvovaginal Candidiasis Manufacturing Base, Sales Area and Its Competitors
Table 134. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Offered
Table 135. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 136. Cisen Pharmaceutical Main Business
Table 137. Cisen Pharmaceutical Latest Developments
Table 138. Kingyork Group Basic Information, Drugs for Vulvovaginal Candidiasis Manufacturing Base, Sales Area and Its Competitors
Table 139. Kingyork Group Drugs for Vulvovaginal Candidiasis Product Offered
Table 140. Kingyork Group Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 141. Kingyork Group Main Business
Table 142. Kingyork Group Latest Developments
List of Figures
Figure 1. Picture of Drugs for Vulvovaginal Candidiasis
Figure 2. Drugs for Vulvovaginal Candidiasis Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Drugs for Vulvovaginal Candidiasis Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Drugs for Vulvovaginal Candidiasis Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Drugs for Vulvovaginal Candidiasis Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Cream
Figure 10. Product Picture of Pessary
Figure 11. Product Picture of Other
Figure 12. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2021
Figure 13. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2017-2022)
Figure 14. Drugs for Vulvovaginal Candidiasis Consumed in Hospital & Clinic
Figure 15. Global Drugs for Vulvovaginal Candidiasis Market: Hospital & Clinic (2017-2022) & (K Units)
Figure 16. Drugs for Vulvovaginal Candidiasis Consumed in Pharmacy
Figure 17. Global Drugs for Vulvovaginal Candidiasis Market: Pharmacy (2017-2022) & (K Units)
Figure 18. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2017-2022)
Figure 19. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application in 2021
Figure 20. Drugs for Vulvovaginal Candidiasis Revenue Market by Company in 2021 ($ Million)
Figure 21. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Company in 2021
Figure 22. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Geographic Region (2017-2022)
Figure 23. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Geographic Region in 2021
Figure 24. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2017-2022)
Figure 25. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country/Region in 2021
Figure 26. Americas Drugs for Vulvovaginal Candidiasis Sales 2017-2022 (K Units)
Figure 27. Americas Drugs for Vulvovaginal Candidiasis Revenue 2017-2022 ($ Millions)
Figure 28. APAC Drugs for Vulvovaginal Candidiasis Sales 2017-2022 (K Units)
Figure 29. APAC Drugs for Vulvovaginal Candidiasis Revenue 2017-2022 ($ Millions)
Figure 30. Europe Drugs for Vulvovaginal Candidiasis Sales 2017-2022 (K Units)
Figure 31. Europe Drugs for Vulvovaginal Candidiasis Revenue 2017-2022 ($ Millions)
Figure 32. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales 2017-2022 (K Units)
Figure 33. Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue 2017-2022 ($ Millions)
Figure 34. Americas Drugs for Vulvovaginal Candidiasis Sales Market Share by Country in 2021
Figure 35. Americas Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country in 2021
Figure 36. United States Drugs for Vulvovaginal Candidiasis Revenue Growth 2017-2022 ($ Millions)
Figure 37. Canada Drugs for Vulvovaginal Candidiasis Revenue Growth 2017-2022 ($ Millions)
Figure 38. Mexico Drugs for Vulvovaginal Candidiasis Revenue Growth 2017-2022 ($ Millions)
Figure 39. Brazil Drugs for Vulvovaginal Candidiasis Revenue Growth 2017-2022 ($ Millions)
Figure 40. APAC Drugs for Vulvovaginal Candidiasis Sales Market Share by Region in 2021
Figure 41. APAC Drugs for Vulvovaginal Candidiasis Revenue Market Share by Regions in 2021
Figure 42. China Drugs for Vulvovaginal Candidiasis Revenue Growth 2017-2022 ($ Millions)
Figure 43. Japan Drugs for Vulvovaginal Candidiasis Revenue Growth 2017-2022 ($ Millions)
Figure 44. South Korea Drugs for Vulvovaginal Candidiasis Revenue Growth 2017-2022 ($ Millions)
Figure 45. Southeast Asia Drugs for Vulvovaginal Candidiasis Revenue Growth 2017-2022 ($ Millions)
Figure 46. India Drugs for Vulvovaginal Candidiasis Revenue Growth 2017-2022 ($ Millions)
Figure 47. Australia Drugs for Vulvovaginal Candidiasis Revenue Growth 2017-2022 ($ Millions)
Figure 48. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Country in 2021
Figure 49. Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country in 2021
Figure 50. Germany Drugs for Vulvovaginal Candidiasis Revenue Growth 2017-2022 ($ Millions)
Figure 51. France Drugs for Vulvovaginal Candidiasis Revenue Growth 2017-2022 ($ Millions)
Figure 52. UK Drugs for Vulvovaginal Candidiasis Revenue Growth 2017-2022 ($ Millions)
Figure 53. Italy Drugs for Vulvovaginal Candidiasis Revenue Growth 2017-2022 ($ Millions)
Figure 54. Russia Drugs for Vulvovaginal Candidiasis Revenue Growth 2017-2022 ($ Millions)
Figure 55. Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Country in 2021
Figure 56. Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country in 2021
Figure 57. Egypt Drugs for Vulvovaginal Candidiasis Revenue Growth 2017-2022 ($ Millions)
Figure 58. South Africa Drugs for Vulvovaginal Candidiasis Revenue Growth 2017-2022 ($ Millions)
Figure 59. Israel Drugs for Vulvovaginal Candidiasis Revenue Growth 2017-2022 ($ Millions)
Figure 60. Turkey Drugs for Vulvovaginal Candidiasis Revenue Growth 2017-2022 ($ Millions)
Figure 61. GCC Country Drugs for Vulvovaginal Candidiasis Revenue Growth 2017-2022 ($ Millions)
Figure 62. Manufacturing Cost Structure Analysis of Drugs for Vulvovaginal Candidiasis in 2021
Figure 63. Manufacturing Process Analysis of Drugs for Vulvovaginal Candidiasis
Figure 64. Industry Chain Structure of Drugs for Vulvovaginal Candidiasis
Figure 65. Channels of Distribution
Figure 66. Distributors Profiles
